Lifeboat Foundation

Summary: Artificial neural networks help researchers uncover new clues as to why people on the autism spectrum have trouble interpreting facial expressions.

Source: Tohoku University.

People with autism spectrum disorder have difficulty interpreting facial expressions.

Summary: Study reveals a link between corticosteroid receptors and genes associated with ciliary and neuroplasticity in the hippocampus, an area of the brain associated with stress response, learning, and memory.

Source: University of Bristol.

Chronic stress is a well-known cause of mental health disorders. New research has moved a step forward in understanding how glucocorticoid hormones (‘stress hormones’) act upon the brain and what their function is. The findings could lead to more effective strategies in the prevention and treatment of mental health disorders.

An electric propulsion specialist and a supercar designer have partnered up on an eye-catching three-seat eVTOL, claiming 250-mph (400 km/h) top speeds and extraordinary 300-mile (483-km) range figures, as well as some extreme flight dynamics and some nifty ideas.

Pete Bitar has been working on vertical propulsion systems for decades now. He’s got a DARPA contract to develop his electric jetpack designs, his Verticycle is a competitor in the GoFly personal flight challenge, and he’s just won one of nine NASA “Future-Scaping Our Skies” awards for his work on ground infrastructure and air traffic control for the coming eVTOL age.

Now he’s partnered up with automotive designer Carlos Salaff to start an eVTOL company. Salaff was behind the outrageous Mazda Furai concept, and has in more recent years been showing his own outrageous coach-built creations at events such as Pebble Beach.

No, it’s not forbidden to innovate, quite the opposite, but it’s always risky to do something different from what people are used to. Risk is the middle name of the bold, the builders of the future. Those who constantly face resistance from skeptics. Those who fail eight times and get up nine.

(Credit: Adobe Stock)

Fernando Pessoa’s “First you find it strange. Then you can’t get enough of it.” contained intolerable toxicity levels for Salazar’s Estado Novo (Portugal). When the level of difference increases, censorship follows. You can’t censor censorship (or can you?) when, deep down, it’s a matter of fear of difference. Yes, it’s fear! Fear of accepting/facing the unknown. Fear of change.

Continue reading “Innovation is a risk!” »

A pair of researchers has shown that trying to classify groups of numbers called “torsion-free abelian groups” is as hard as it can possibly be.

The same process that eliminates replication errors also eliminates antiviral agents delivered by the treatments commonly used to fight other RNA viruses, such as HIV, HCV and Ebola virus, which partially explains why SARS-CoV-2 has proven so difficult to treat, Yang said.

The coronavirus that causes COVID-19 has demonstrated a stubborn ability to resist most nucleoside antiviral treatments, but a new study led by an Iowa State University scientist could help to overcome the virus’s defenses.

The study, published recently in the peer-reviewed journal Science, details the structure of a critical enzyme present in SARS-CoV-2, the coronavirus that causes COVID-19. This enzyme, known as the proofreading exoribonuclease (or ExoN), removes nucleoside antiviral medications from the virus’s RNA, rendering most nucleoside analogs-based antiviral treatments ineffective. The new study presents the atomic structures of the ExoN enzyme, which could lead to the development of new methods for deactivating the enzyme and opening the door to better treatments for patients suffering from COVID-19.

Continue reading “The enzyme that allows coronavirus to resist antiviral medications” »

The habits and flaws tycoons share with dynastic rulers | Business.

The social networking giant and its CEO have vast ambitions to dominate the next big thing in computing, but other tech giants are in a better position to turn the hype into reality.

A group of medications long prescribed to treat tapeworm has inspired a compound that shows two-pronged effectiveness against COVID-19 in laboratory studies, according to a new publication appearing online in the journal ACS Infectious Disease.

The compound, part of a class of molecules called salicylanilides, was designed in the laboratory of Professor Kim Janda, Ph.D., the Ely R. Callaway, Jr. Professor of Chemistry and director of the Worm Institute for Research and Medicine at Scripps Research, in La Jolla, CA. “It has been known for 10 or 15 years that salicylanilides work against certain viruses,” Janda says. “However, they tend to be gut-restricted and can have toxicity issues.” Janda’s compound overcomes both issues, in mouse and cell-based tests, acting as both an antiviral and an anti-inflammatory drug-like compound, with properties that auger well for its use in pill form.